Online inquiry

IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11221MR)

This product GTTS-WQ11221MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets pcrV&psl gene. The antibody can be applied in P. Aeruginosa nosocomial pneumonia research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Humanized
RefSeq WP_003100789.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID O30527
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11221MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9353MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ12067MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ14092MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ6936MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ENIA11
GTTS-WQ10036MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA L19-131 I
GTTS-WQ7137MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ14214MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ12257MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MRA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW